You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

~ Buy the VYONDYS 53 (golodirsen) Drug Profile, 2024 PDF Report in the Report Store ~

VYONDYS 53 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vyondys 53 patents expire, and when can generic versions of Vyondys 53 launch?

Vyondys 53 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has thirty patent family members in thirteen countries.

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this compound. Additional details are available on the golodirsen profile page.

DrugPatentWatch® Generic Entry Outlook for Vyondys 53

Vyondys 53 was eligible for patent challenges on December 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2026. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for VYONDYS 53
International Patents:30
US Patents:8
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for VYONDYS 53
What excipients (inactive ingredients) are in VYONDYS 53?VYONDYS 53 excipients list
DailyMed Link:VYONDYS 53 at DailyMed
Drug patent expirations by year for VYONDYS 53
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VYONDYS 53
Generic Entry Date for VYONDYS 53*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VYONDYS 53

VYONDYS 53 is protected by eight US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VYONDYS 53 is ⤷  Sign Up.

This potential generic entry date is based on INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VYONDYS 53

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting VYONDYS 53

INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
Exclusivity Expiration: ⤷  Sign Up

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc VYONDYS 53 golodirsen SOLUTION;INTRAVENOUS 211970-001 Dec 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sarepta Theraps Inc VYONDYS 53 golodirsen SOLUTION;INTRAVENOUS 211970-001 Dec 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Sarepta Theraps Inc VYONDYS 53 golodirsen SOLUTION;INTRAVENOUS 211970-001 Dec 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VYONDYS 53

When does loss-of-exclusivity occur for VYONDYS 53?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 98685
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0110352
Estimated Expiration: ⤷  Sign Up

Patent: 0160225
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 11447
Estimated Expiration: ⤷  Sign Up

Patent: 17475
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 66010
Estimated Expiration: ⤷  Sign Up

Patent: 06781
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 66010
Estimated Expiration: ⤷  Sign Up

Patent: 06781
Estimated Expiration: ⤷  Sign Up

Patent: 05200
Estimated Expiration: ⤷  Sign Up

Patent: 00430
Estimated Expiration: ⤷  Sign Up

Patent: 33332
Estimated Expiration: ⤷  Sign Up

Patent: 29142
Estimated Expiration: ⤷  Sign Up

Patent: 28711
Estimated Expiration: ⤷  Sign Up

Patent: 08845
Estimated Expiration: ⤷  Sign Up

Patent: 47096
Estimated Expiration: ⤷  Sign Up

Patent: 72748
Estimated Expiration: ⤷  Sign Up

Germany

Patent: 2005026386
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 16545
Estimated Expiration: ⤷  Sign Up

Patent: 45325
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 28632
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 66010
Estimated Expiration: ⤷  Sign Up

Patent: 06781
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 66010
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 66010
Estimated Expiration: ⤷  Sign Up

Patent: 06781
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 61325
Estimated Expiration: ⤷  Sign Up

Patent: 64185
Estimated Expiration: ⤷  Sign Up

Patent: 27917
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYONDYS 53 around the world.

Country Patent Number Title Estimated Expiration
Denmark 1766010 ⤷  Sign Up
Japan 5425396 ⤷  Sign Up
Canada 2584599 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.